Pembrolizumab After Platinum Linked to Longer Survival in 147 Uterine Carcinosarcoma Patients

Seventeen years of cases in one series

The study window opens in January 2008 and closes in April 2025, which is long enough that the earliest patients were treated years before any checkpoint inhibitor was available for gynecologic cancers and the latest were treated after combinations became routine. Patients entered on a diagnosis of metastatic or recurrent uterine carcinosarcoma and went on to varied regimens after recurrence or progression in the post-platinum setting. First author Yen-Ling Lai works at National Taiwan University Hospital Hsin-Chu Branch, and the corresponding authors are Yu-Li Chen at National Taiwan University Hospital and Yoo-Young Lee of the gynecologic oncology division at Samsung Medical Center, Sungkyunkwan University School of Medicine in Seoul. Two pathologists are on the byline: Koping Chang of the National Taiwan University Hospital pathology department and Hyun-Soo Kim of pathology and translational genomics at Samsung Medical Center. The authors declare no competing interests.

Four models for one comparison

Retrospective comparisons of treated against untreated patients in a recurrent-disease cohort carry an obvious hazard: patients who live longer have more opportunity to receive a later-line drug. The authors addressed it with Kaplan-Meier estimates and Cox proportional hazards models, then added inverse probability of treatment weighting, an estimator that stays valid when either the treatment model or the outcome model is correctly specified, and time-dependent Cox models. The result of that stack is the most informative number in the paper. Survival after recurrence stayed significant under weighting, at 0.56 with a confidence interval reaching 0.96, while the overall survival benefit that looked convincing in the unweighted multivariable model did not survive the adjustment.

Cytology, and the biomarkers the abstract does not report

Positive peritoneal washing cytology emerged as an independent predictor of poorer outcomes, a finding that puts a routine cytology result alongside the treatment variable in the same model. What the abstract does not carry is any breakdown by mismatch repair status, microsatellite instability or PD-L1 expression, and no assay, scoring system or specimen source appears in it. Lenvatinib sits in the paper's keyword list, which suggests combination regimens are represented in the treated group, though the abstract gives no split between pembrolizumab alone and pembrolizumab with a partner drug. Elsevier holds the full article and no PubMed Central copy was deposited. Only the structured abstract and the indexed record could be read for this report.

Why This Matters to the APO|APE Reader

Study 309/KEYNOTE-775, which established lenvatinib plus pembrolizumab in previously treated advanced endometrial carcinoma, explicitly excluded carcinosarcoma along with endometrial leiomyosarcoma and stromal sarcomas, leaving this histology outside the randomized evidence that shapes practice for the rest of the uterine corpus. A 42-patient treated group assembled across two countries over 17 years is what stands in that gap, and the authors ask for prospective validation on exactly those grounds. Until a trial enrolls these patients, the tissue questions matter more than usual: whichever center performs the mismatch repair immunohistochemistry decides which patients are even considered for the drug.